QCM
MLYS icon

Quantinno Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Quantinno Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$799K Buy
29,629
+9,088
+44% +$249K ﹤0.01% 2730
2026
Q1 		$556K Buy
20,541
+2,298
+13% +$67.4K ﹤0.01% 2637
2025
Q4 		$662K Sell
18,243
-384
-2% -$15.4K ﹤0.01% 2137
2025
Q3 		$706K Buy
18,627
+5,030
+37% +$109K ﹤0.01% 1718
2025
Q2 		$184K Buy
13,597
+859
+7% +$12.4K ﹤0.01% 2386
2025
Q1 		$202K Buy
+12,738
New +$147K ﹤0.01% 1880

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Quantinno Capital Management's MLYS Position: Q2 2026 in Review

Quantinno Capital Management increased its Mineralys Therapeutics (MLYS) stake by 44% in Q2 2026, buying an estimated $249K and bringing the position to 29,629 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #2730.

Quantinno Capital Management first reported a position in MLYS in Q1 2025 and has held it in 6 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Quantinno Capital Management held 29,629 shares of Mineralys Therapeutics worth $799K as of Q2 2026.
  • Quantinno Capital Management bought 9,088 Mineralys Therapeutics shares in Q2 2026, an estimated $249K.
  • Mineralys Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2730 holding.
  • Quantinno Capital Management first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.